Dose Ranging and Dose Frequency of LIPO-102

Neothetics

Status and phase: Completed; Phase 2

Conditions: Subcutaneous Adipose Tissue Reduction

Treatments: Drug: LIPO-102; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00918814

LIPO-102-CL-03

Details and patient eligibility

About

Dose Ranging and Dose Frequency of LIPO-102

Enrollment: 54 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or non pregnant female
• Good general health
• Sufficient abdominal fat for injections
• Signed informed consent

Exclusion criteria

• Known hypersensitivity to study drugs
• Treatment with an investigational agent within 30 days of first dose

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

54 participants in 2 patient groups

LIPO-102

Experimental group

Description:

LIPO-102

Treatment:

Drug: LIPO-102

Placebo

Experimental group

Description:

Placebo

Treatment:

Drug: Placebo